Immunotactoid glomerulopathy (ITG) is a rare glomerular disease characterized by protein deposition in hollow microtubules on electron microscopy. Patients may present with proteinuria, hematuria, hypertension, and renal insufficiency, and some patients even progress to end-stage renal disease (ESRD). In patients with ESRD, ITG recurs in more than 50% of patients after kidney transplantation; however, there is no clear treatment plan for these patients owing to the limited number of reported cases. In this study, we report a case of a 58-year-old male who was admitted to our hospital with elevated blood creatinine with proteinuria. Renal biopsy suggested membranoproliferative glomerulonephritis with findings suggestive of ITG on electron microscopy. After the first diagnosis of renal insufficiency, the patient was treated with rituximab; however, the patient's symptoms did not improve, and blood creatinine continued to increase. The patient progressed to ESRD, and 3 years later, kidney transplantation was performed. After surgery, he was regularly treated with tacrolimus, mycophenolate mofetil, and prednisone acetate for antirejection. Five months after surgery, a renal biopsy was performed again due to proteinuria, and the results suggested ITG recurrence. The patient's blood CD19-positive B-cell count was 0. Therefore, he was not administered rituximab again. The patient is now under regular review; his blood creatinine is relatively stable (120-150 mmol/L), while his 24-hour urine protein quantification is higher than the normal range. This study expands the number of reported cases of this condition and will be useful to better understand the treatment options for patients with ITG recurrence after kidney transplantation.
Yu et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: